Last reviewed 2026-06-03 · How we verify

Biguanide, DPP4 inhibitors, SGLT2 inhibitors

Metabolic Research Unit · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

Biguanide, DPP4 inhibitors, SGLT2 inhibitors is a Small molecule drug developed by Metabolic Research Unit. It is currently in Phase 1 development.

Here's a 2-sentence factual summary of Biguanide, DPP4 inhibitors, and SGLT2 inhibitors: Biguanides, DPP4 inhibitors, and SGLT2 inhibitors are oral antidiabetic medications used to treat Type 2 Diabetes, as indicated by ClinicalTrials.gov. These medications have been studied for their effects on visceral fat in Type 2 Diabetes patients, as seen in the pilot study "ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT" (NCT05032001) on ClinicalTrials.gov.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Biguanide, DPP4 inhibitors, SGLT2 inhibitors
Sponsor	Metabolic Research Unit
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Biguanide, DPP4 inhibitors, SGLT2 inhibitors CI brief — competitive landscape report
Biguanide, DPP4 inhibitors, SGLT2 inhibitors updates RSS · CI watch RSS
Metabolic Research Unit portfolio CI

Frequently asked questions about Biguanide, DPP4 inhibitors, SGLT2 inhibitors

What is Biguanide, DPP4 inhibitors, SGLT2 inhibitors?

Biguanide, DPP4 inhibitors, SGLT2 inhibitors is a Small molecule drug developed by Metabolic Research Unit.

Who makes Biguanide, DPP4 inhibitors, SGLT2 inhibitors?

Biguanide, DPP4 inhibitors, SGLT2 inhibitors is developed by Metabolic Research Unit (see full Metabolic Research Unit pipeline at /company/metabolic-research-unit).

What development phase is Biguanide, DPP4 inhibitors, SGLT2 inhibitors in?

Biguanide, DPP4 inhibitors, SGLT2 inhibitors is in Phase 1.

Manufacturer: Metabolic Research Unit — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing